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Impairment of fertility and sexual/reproductive health are common after oncologic therapy, and are known to have
negative impacts on romantic relationships and psychosocial well-being among childhood cancer survivors. The
Pediatric Initiative Network (PIN) is an international, multidisciplinary group of providers within the Oncofertility
Consortium dedicated to preserving and protecting the fertility of children and adolescents at risk for infertility due to
medical conditions or treatments. The PIN and its Best Practices and Research committees meet virtually throughout
the year, with one annual in-person meeting. The purpose of this ‘‘proceedings’’ is to highlight key discussion points
from the annual PIN meeting which took place on November 11, 2019, to 1) provide a context for pediatric groups
across the country on what oncofertility programs are currently doing and why, and 2) inform stakeholders of past,
present and future initiatives that may be of value to them and the patient populations they serve.
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Introduction
Nearly 300,000 individuals under the age of 20 arediagnosed with cancer around the world each year.1
Treatment advances have led to increasing survival rates,
highlighting the importance of addressing and mitigating late
effects of oncologic therapies.2,3 For example, impairment of
fertility and sexual/reproductive health often occur due to
surgery, chemotherapy, and radiation and are known to have
negative impacts on future romantic relationships and psy-
chosocial well-being.3–9 These are uniquely challenging
topics to consider in the pediatric and adolescent age group,
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as (1) established fertility preservation (FP) technologies
have not historically been available for prepubertal youth; (2)
developmental considerations may limit capacity for future-
oriented planning, including formation of parenthood goals
and FP decisions; (3) shared decision making models are
needed to facilitate discussions between providers, parents,
and patients; and (4) ethical and legal challenges often arise
during discussions about these topics among minors. To op-
timize long-term psychosocial and reproductive outcomes,
there is a critical need for providers from different disciplines
and regions to collaborate to establish evidence-based ‘‘best’’
oncofertility practices for pediatric and adolescent populations.
The Pediatric Initiative Network (PIN) is an international
group of providers within the Oncofertility Consortium
dedicated to preserving and protecting the fertility of children
and adolescents at risk for infertility due to medical condi-
tions or treatments.10–12 In a span of 6 years, the PIN has
established itself as an integral and necessary component of
the Oncofertility Professional Engagement Network (OPEN)
of the Oncofertility Consortium and a strengthening voice
within the field.13 The group has grown rapidly, with 102
active members from 62 institutions, including physicians,
researchers, advanced practitioners, nurses, psychologists,
social workers, patient navigators, and trainees from each of
these groups. Numerous medical disciplines are represented,
including oncology, endocrinology, pediatric gynecology,
reproductive endocrinology, and urology. Two major com-
mittees have been established within the PIN—Best Prac-
tices and Research. There are no dues or requirements to join
the PIN; individuals can email the PIN Chair and committee
chairs, explaining their involvement in oncofertility and
interest in joining: http://oncofertility.northwestern.edu/
pediatric-initiative-network. The PIN and its committees/
subcommittees meet virtually (through WebEx/conference
calls/emails/listservs) throughout the year and with one an-
nual in-person meeting. The purpose of this ‘‘proceedings’’ is
to highlight key discussion points from the annual PIN
meeting, which took place on November 11, 2019, in Chi-
cago, IL, to 1) provide a context for pediatric groups across
the country on what oncofertility programs are currently
doing and why, and 2) inform stakeholders of past, present,
and future initiatives that may be of value to them and the
patient populations they serve.
Oncofertility Program Development: Successes
and Ongoing Challenges
A total of 103 people from 60+ institutions in 10 countries
participated in the 2019 PIN meeting. The first main agenda
item was to discuss oncofertility program development, in-
cluding the following key questions: (1) which institutions
have a formal FP/reproductive health program; (2) which
programs have a dedicated patient navigator/coordinator;
(3) are reproductive endocrinologists and urologists avail-
able to perform FP procedures as needed; (4) which strate-
gies have been implemented to maximize access; (5) what
are ongoing barriers; (6) are ovarian tissue cryopreservation
(OTC) and testicular tissue cryopreservation (TTC) being of-
fered and to which patient populations; and (7) how are costs
being handled for cryopreservation, processing, and storage?
Of the represented institutions, 31 reported having a formal
FP program, and 13 of those had a dedicated patient navi-
gator/coordinator. In the United States, OTC is currently
offered at 16 of these institutions, and TTC is offered at 12.
Representatives from other countries reported their experi-
ences as well; for example, attendees from Japan reported
that there are over 42 centers offering tissue cryopreservation
in their country. All of the institutions offering tissue cryo-
preservation included gonadotoxic cancer therapy and bone
marrow transplant for nononcologic conditions as indica-
tions, but only select institutions were including patients with
differences of sex development, rheumatologic disorders
requiring high dose cyclophosphamide, Turner Syndrome,
genetic predispositions to primary ovarian insufficiency, or
transgender patients. Financial considerations were fre-
quently noted to be a concern, with several of the institutions
offering tissue processing for OTC at no charge to the patient
(e.g., using research funds since it has historically been
considered experimental), and others offer processing for
$400–1000. The majority of programs reported surgical costs
for OTC ranging from $5000 to $8000; those billing insur-
ance reported that coverage had been inconsistent and un-
predictable. Access to established FP procedures (e.g., oocyte
cryopreservation and testicular sperm extraction) was not
universal. Of the represented institutions, 20 had access to a
reproductive endocrinologist if needed for pediatric and ad-
olescent FP, and 19 had a readily available reproductive
urologist.
Attendees with established FP programs at their institu-
tions also discussed ways to maximize patient access to FP
services. Four programs described an ‘‘opt-out’’ fertility
consult embedded in the oncology order set,14 2 programs
used a ‘‘hard stop’’ to inquire about FP in the electronic
medical record (EMR), and several others described dedi-
cated inpatient/outpatient order sets for FP. Participants from
several other institutions reported receiving patient lists of
upcoming patients, either for tumor board meetings or for
state reporting purposes. Ease of referral also improved ac-
cess, including having a patient navigator/coordinator and
having a dedicated email address including the entire FP
team. Education of floor nurses and house officers was also
identified as a strategy to increase referrals, with some pro-
grams incorporating information about FP into hospital ori-
entation. Finally, one program reported implementing a
policy that floor nurses can place the order for the FP consult
(similar to how a nurse can request a social work consult),
which was anticipated to increase inpatient consults.
Several barriers to program implementation and success
were also identified. Even among those institutions with es-
tablished FP programs, all but one institution felt their pro-
gram could be improved. One of the biggest barriers
identified was related to funding—both for program building
and to assist with patient costs. Ongoing difficulties securing
philanthropy were discussed, and several who had secured
philanthropic funds to assist patients noted concerns about
this approach potentially being viewed as ‘‘enticement’’ or
‘‘coercion’’ to pursue FP by institutional ethics boards and
review boards. Participants also discussed difficulty securing
institutional support for protected time for providers to ded-
icate to a FP program or to hire a patient navigator/coordi-
nator. Potential solutions offered by established programs
included having a navigator bill for consult services to help
cover their salary (and considering credentials needed to bill,
for example, advanced practice nurse vs. registered nurse)















































and emphasizing to institution leadership that a formal FP
program is necessary or contributes to national benchmarks
such as U.S. News and World Report rankings (in disciplines
such as Oncology and Urology). Nursing research or spe-
cialty roles are also necessary for nursing magnet status and
can be fulfilled by nurses serving as a patient navigator/co-
ordinator or research coordinator.
The lack of standardization or an accreditation process
across programs in the United States was also identified as a
barrier to programmatic success. It was suggested that quality
indicators be developed for pediatric FP programs, similar to
the system currently in place across Australian programs.
Regarding tissue cryopreservation, programs have found that
slow freezers with which to freeze the tissue are becoming
more scarce, as oocyte and sperm cryopreservation have
moved to vitrification protocols. Some programs have moved
to vitrification of tissue, while others noted the ability to buy
used slow freezers from other programs; there has also been a
trend toward using a centralized tissue cryopreservation
center. Finally, difficulty obtaining institutional review board
(IRB) approval was also noted to be a barrier to tissue
cryopreservation at some institutions, because even when
OTC was considered experimental it wasn’t considered
‘‘research’’ by some IRBs (in the absence of a clear research
question) and TTC has often been considered ‘‘too experi-
mental.’’ Suggestions from institutions who had secured IRB
approval included preemptive discussions with IRB repre-
sentatives before submission or attending the IRB meeting
where the topic is being discussed; FP programs with clinical
research coordinators may be able to navigate these processes
more efficiently. Some programs are pairing a research study
with OTC, such as creating a database or surveying patients
on their experience.
Best Practices Committee
The mission of the Best Practices Committee is to develop
strategies to optimize fertility related care for at-risk youth.
At the annual Oncofertility Consortium meeting, the com-
mittee identifies initiatives important to the PIN and develops
projects that can be accomplished during the subsequent 12
months. During 2019, the Best Practices Committee im-
plemented three initiatives, which were presented at the
meeting: (1) An Infertility Risk Stratification System; (2)
Development of an Oncofertility Patient Navigation Com-
mittee; and (3) A single journal series of review articles
dedicated to Pediatric, Adolescent and Young Adult (AYA)
FP and Reproductive Health in Survivorship.
Risk stratification
The risk stratification project began because of the dis-
crepancies in cut points used to classify level of risk for future
infertility after childhood cancer therapy. The discrepancies
made comparisons across research studies challenging and
led to variability in clinical practice at different sites.
A working group of 27 PIN members reviewed current
methods in use clinically and in research to stratify risk for
infertility, performed a literature review,4,15–29 and then de-
veloped risk stratification grids. Separate stratification grids
were developed for female and male patients categorizing
risk for future infertility/gonadal failure into minimally in-
creased risk, significantly increased risk, and a high level
of increased risk after exposure to gonadotoxic cancer
therapies. The exposures known to place survivors at risk for
infertility/gonadal failure were identified from the Children’s
Oncology Group Long-Term Follow-Up Guidelines for
Survivors of Pediatric, Adolescent, and Young Adult Can-
cers and include: alkylating and heavy metal chemotherapy,
radiation to the gonad or hypothalamus, hematopoietic stem
cell transplant, and surgery on the reproductive tract.15
These grids will soon be published30 to serve as a resource
for clinicians and researchers.
Oncofertility Patient Navigator Subcommittee
During 2019, the Oncofertility Patient Navigator Sub-
committee was established after a national survey of PIN
members demonstrated the essential role of navigators in
providing timely and comprehensive fertility and reproduc-
tive health care to youth and families before, during, and after
cancer treatment.11 This group has expanded rapidly and now
includes 25 participants from 23 institutions across the Uni-
ted States and Australia. Initial efforts to establish this oc-
curred at the 2018 Oncofertility Consortium meeting among
attendees; the subcommittee has expanded over 2019 strictly
by word of mouth. Strategies to further expand membership
within the United States and internationally are underway for
the upcoming year. The group has participated in bimonthly
conference calls throughout the year with three main goals: to
provide a forum to address the unique needs of fertility
navigators; to create a network of cooperative programs in all
stages of development; and to develop navigator specific
projects and contributions to the Oncofertility Consortium. In
early 2019, members initiated a pilot fertility program survey
sent to existing subcommittee members. This work will
continue and expand over the next year with a plan to dis-
seminate to navigators across the Consortium. The survey
will provide program and navigator information for bench-
marking, establish a network for collaboration, and facilitate
access to mentorship for programs during their early stages.
In addition, the Navigator subcommittee coordinated a
working lunch panel presentation during the 2019 Onco-
fertility Consortium Conference entitled ‘‘Fertility Pre-
servation Legislation and Loopholes.’’ The panel focused on
FP insurance mandates, practical approaches to advocacy,
and descriptions of navigator-initiated legislative efforts
seeking funding for FP and reproductive health.
Reproductive health in survivorship
A final project from the 2019 Best Practices Committee
consists of a series of articles focusing on Reproductive
Health in Pediatric and AYA cancer patients, with the plan
for them to be published as a special edition series. The eight
articles will include: Pediatric Reproductive Tumors, Male
Pediatric and AYA Reproductive Survivorship, Female Pe-
diatric and AYA Reproductive Survivorship, Reproductive
Late Effects after BMT, Fertility Considerations in AYA
Survivorship, Psychosexual Functioning in Survivorship,
Reproductive Health Literacy, and Reproductive Care Na-
vigation in Survivorship. The purpose of this effort is to
collate reproductive concerns in cancer survivorship in one
easily referenceable location. Critical gaps discussed in these
reviews include diagnosis and management of diminished
ovarian reserve, identification and treatment of genital graft















































versus host disease, screening and treatment interventions for
sexual dysfunction, reproductive cancer surveillance, and
hormone replacement in the setting of comorbidities. The
articles will serve as the basis of future prospective research
to address these critical gaps in care.
Future Best Practices committee initiatives
After soliciting ideas from the PIN membership and as-
certaining the interest of members to participate in working
groups, the 2020 Best Practices initiative will evaluate the use
of Anti-Mullerian hormone (AMH) in survivors of childhood
cancer. AMH has become the best currently available marker
of ovarian reserve and has aided in counseling patients about
their reproductive life span, as well as the effects of gona-
dotoxic therapy during cancer treatment. Several studies have
reported the use of AMH in evaluating ovarian reserve in
pediatric cancer patients who have undergone gonadotoxic
therapy.31–35 However, while these studies collectively sug-
gest that AMH is a sensitive marker for damage to the ovarian
reserve, there are currently little data regarding how and
when to use AMH as a screening tool in the survivorship
population. In fact, current surveillance recommendations in
female childhood cancer survivors from the International
Late Effects of Childhood Cancer Guideline Harmonization
Group do not recommend using AMH as a primary surveil-
lance modality for primary ovarian insufficiency.16 Much of
the reasoning for not recommending AMH as a standard
method of surveillance is due to the lack of literature on AMH
in this population. Nevertheless, AMH has been a helpful
addition in the counseling and identification of patients who
may have a narrowed window of reproductive potential
secondary to their therapy, and further understanding of how
AMH is used in the survivorship population may provide a
benefit to future patients and providers.
In a breakout session, the working groups convened and
identified project leaders, defined the goals of the project, and
began to create next steps and timelines. This project will
begin with a review of the current evidence regarding AMH
surveillance in pediatric oncology survivors through a sys-
tematic review. Second, oncofertility practitioners in the PIN
will be surveyed to evaluate current practices regarding AMH
screening in female childhood cancer survivors. This will
include questions surrounding who AMH testing is ordered
on, at which timepoint(s) in the survivorship continuum, and
when to refer these patients to a Reproductive Endocrinology
and Infertility specialist. Analyzing and disseminating these
data will serve as an important initial step to establishing best
practices for the use of AMH in the survivorship population.
Research Committee
The mission of the PIN Research Committee is to design
and implement collaborative multisite research studies to
advance fertility related care for at-risk youth. As more in-
stitutions implement FP programs, many questions remain to
be studied such as: patients’ and families’ understanding of
and decision-making around FP options (both established and
experimental), risks of immediate or delayed gonadal failure
of older and newer therapeutic agents, long-term effects of FP
procedures, as well as the ascertainment of ovarian reserve in
children and adolescents. The ability to share information
across sites for the purpose of research is essential, allowing a
broad and expansive population base to answer these im-
portant questions. Given the increasing use of OTC and the
relevance of this technology in pediatric populations, crea-
tion of a centralized OTC database was the main focus of the
research committee in 2019.
OTC database: lessons learned and future directions
Although databases have been established in other coun-
tries, data and literature regarding OTC research questions
remain scarce, especially regarding children and adolescents.
In addition, there are regional and national differences in
OTC indications and practice. The PIN’s initial endeavor in
U.S. OTC database creation resulted in the discovery that
individual U.S. sites are both interested and incentivized to
participate in a shared centralized database to share ideas and
obtain IRB research approval. To date, four U.S. sites have
obtained IRB approval to collect patient data in a centralized
database, and three sites have entered anonymous patient
information as part of their IRB approved OTC protocols.
Several institutions note that the addition of the centralized
database was necessary to fulfill the research requirement of
their local IRB and obtain full approval for OTC protocols.
Moreover, we discovered that conducting a successful
multisite database requires research support from a central data
manager. Although many sites were able to obtain IRB ap-
proval and have internally funded research coordinators enter
data, it became clear that a central coordinator is essential for
‘‘managing the database’’ and assuring data integrity. This
central coordinator facilitates sharing of protocols, coordinates
data-use agreements between distinct legal departments, and
coordinates access to the database for each site. This coordi-
nator can also manage transfer of deidentified data from ex-
isting databases into the centralized location, as well as send
ongoing reminders to continue populating data.
Based on this prior experience, as well as that of the
Australasian Oncofertility registry,36 FertiPROTEKT regis-
try,37 and Japanese FP registry,38 in an effort to create a
central repository for U.S. data regarding patients who have
undergone OTC, the PIN Research Committee has decided to
proceed with an effort to create a central repository for data
regarding patients who have undergone OTC by: (1) revising
all OTC data collection sheets into an updated centralized
database to maximize information collected regarding the
specifics of treatment, surgery, endocrine function, and ob-
stetrical outcomes; (2) transitioning the database to a cen-
tralized site where there is institutional support for this
endeavor with a research coordinator, database manager,
designated legal team, and local grant funding for the lon-
gevity of the program; and (3) promoting vigorous academic
output by encouraging each participating site to take own-
ership and submit research ideas, commit to participating in
the chosen research idea, and have equal opportunity for
authorship on every publication resulting from the database.
Future research projects
Discussion during the 2019 meeting also revealed interest
in other research ideas and broader data collection regarding
FP in general:
(1) Creating a TTC database: This project can be facili-
tated by previous experience with the OTC database.















































Using the same site and resources would allow a
faster production of the database, and the fact that to
date all TTC protocols are part of an ongoing single
network will allow easier uptake of such a protocol
and data collection at current participating sites.
(2) Optimizing basic tissue research: Although OTC is
no longer considered experimental, questions remain
regarding best practices for cryopreservation (e.g.,
slow freezing vs. vitrification) and retransplantation
versus in vitro maturation of follicles, particularly
from tissue obtained from prepubertal girls. Collec-
tion of tissue for basic research will improve
knowledge about handling ovarian tissue for FP and
future use of the tissue, which will undoubtedly im-
prove outcomes for patients who choose OTC as a FP
method. Data regarding who is doing tissue research
and who is collecting tissue for research are important
to enable sites to link together for future collabora-
tion. Given the relatively small number of sites col-
lecting tissue and actually performing research on this
tissue, creating such a list was fairly simple. The
decision was made that this database would be main-
tained within the PIN Research Committee and up-
dated yearly. Furthermore, the committee realized that
there is a need to optimize the utilization of stored
tissue. Current members of the PIN intend to apply for
NIH funding to explore best ways to maximize tissue
use including but not limited to:
(i) Creating a digital library of current slide book to
be shared among investigators.
(ii) Evaluating the best ways to process existing
block tissues to maximize use.
(iii) Creating a system for investigators to submit
proposals and for a team to review, score, and
decide on which studies merit the ability to use
precious tissues such as these.
(3) FP Decision-Making: Researchers within the PIN
have defined study questions around FP decision-
making (e.g., predictors of OTC/TTC uptake, factors
impacting fertility testing after treatment) and would
like to collaborate with sites that have FP programs.
A more detailed future database may also allow direct
access to sites and patients in the future.
(4) General FP Database: This database would include
data from all existing FP programs throughout the
PIN. Several sites are collecting detailed data re-
garding their fertility program. Given EMR cap-
abilities and support at a single site, in the future it
may be possible to collect detailed data from the
EMR. As such, the first step would be to create a
‘‘data dictionary’’ to assure that all sites are collect-
ing the same data. Furthermore, international mem-
bers will share their experience and data points from
their national databases. A subcommittee plans to
spend the next year refining a possible future data
collection dictionary for PIN participants.
Conclusions
The PIN has steadily expanded from a small network of
dedicated individuals to an international multidisciplinary
platform for research collaboration and integration of best
practices in pediatric oncofertility. This growth reflects the
increasing importance of pediatric oncofertility, as three-
fourths of childhood cancer survivors will experience at least
one late effect of cancer treatment. Despite the potentially
life-threatening sequelae of cardiac, pulmonary, and renal
toxicity, reproductive late effects remain one of the most
reported quality of life disruptors for survivors.3,39 Sig-
nificant advancements have been made in mitigating repro-
ductive late effects of gonadal insufficiency, infertility,
genital graft-versus-host disease, sexual dysfunction, and
radiation effects to the pelvic organs.22,40 Innovations in the
application of assisted reproductive technologies (ART) to
patients with cancer have decreased time to ART, improved
safety of ART in patients with hormone sensitive tumors, and
provided options for patients for whom ART are not feasible.
Successful application of newly established FP therapies to
the pediatric and adolescent population will require focused
investigation in current areas of challenge such as family-
centered FP decision-making, the applicability of AMH
testing, feasibility of oocyte cryopreservation in the imme-
diate postpubertal patient, efficiency of transplanted ovarian
and testicular tissue, early identification and evidenced-based
treatment of gynecologic and urologic late effects, and
methods of effective data collection to more rapidly inves-
tigate and apply knowledge. Key Performance Indicators,
competency frameworks, and effective communication
strategies are also essential to optimal outcomes and will
require dedicated effort.
The PIN harnesses the knowledge, curiosity, and desire for
innovation of interdisciplinary experts and newcomers to the
field. Progress requires medical providers, mental health
specialists, basic scientists, stakeholders, economists, ethi-
cists, and legal scholars. OPEN established a setting for
convening these specialists through which the PIN was born
and flourished to be an integral sector. PIN members work
through the network to improve options and access not only
for survivors of childhood cancer but also other pediatric
medical conditions with impaired fertility potential. Quality
of life in pediatric populations is dependent on the ability of
our field to anticipate, innovate, implement, and critically
evaluate to improve the care provided to patients. This col-
laborative power uniquely positions the PIN to meet the
challenge. Future endeavors will focus on addressing the
most pressing of challenges while expanding the reach and
scope of the PIN.
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